Bystander effects, pharmacokinetics, and linker-payload stability of EGFR-targeting antibody-drug conjugates Losatuxizumab vedotin and Depatux-M in glioblastoma models.
Jain S, Griffith JI, Porath KA, Rathi S, Le J, Pasa TI, Decker PA, Gupta SK, Hu Z, Carlson BL, Bakken K, Burgenske DM, Feldsien TM, Lefebvre DR, Vaubel RA, Eckel-Passow JE, Reilly EB, Elmquist WF, Sarkaria JN.
Jain S, et al. Among authors: hu z.
Clin Cancer Res. 2024 May 14. doi: 10.1158/1078-0432.CCR-24-0426. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 38743766